I. COMMENCED TRADING IN MARCH | ||||||||
Company (Symbol) |
Date Filed |
Date Comm. |
Shares/ |
Price |
Shares Out (M) |
Lead, Other Underwriters |
Gross (M) |
Post-Offering Market Cap (M) |
| ||||||||
INITIAL OFFERINGS | ||||||||
There were no initial public offerings conducted in March. | ||||||||
Total: $0M | ||||||||
Number of IPOs in March: 0 | ||||||||
Average value of March IPOs: $0M | ||||||||
Number of IPOs in 2003: 0 | ||||||||
Total raised in IPOs in 2003: $0M | ||||||||
Average value of IPOs in 2003: $0M | ||||||||
| ||||||||
FOLLOW-ON OFFERINGS | ||||||||
| ||||||||
Company (Symbol)# |
Date Filed |
Date Comm. |
Shares/ |
Price |
Shares Out (M)@ |
Lead, Other Underwriters |
Gross (M) |
Post- |
| ||||||||
Bioxel Pharma Inc. (Canada; CDNX:BIP)1 |
11/11/02 |
3/7/03 |
13.6S |
C70 cents |
N/A |
Dundee Securities National Bank Financial Canaccord Capital |
C$9.5 (US$6.5) |
N/A |
|
|
|
|
|||||
Inspire Pharmaceuticals Inc. (ISPH)2 |
1/21/03 |
3/14/03 |
5.75S |
$13.50 |
30.9 |
Deutsch Bank (co-lead) U.S. Bancorp Piper Jaffray (co-lead) |
$77.63 |
$417.15 |
|
||||||||
The Medicines Co. (MDCO)3 |
3/5/03 |
3/14/03 |
4.9S |
$17.50 |
45.7 |
Morgan Stanley (co-lead) Bear, Stearns & Co. (co-lead) CIBC World Markets |
$85.75 |
$799.75 |
|
||||||||
Total: $169.88M | ||||||||
Number of follow-on offerings in March: 3 | ||||||||
Average value of March follow-ons: $56.63M | ||||||||
Number of follow-on offerings in 2003: 7 | ||||||||
Total raised in follow-ons in 2003: $505.935M | ||||||||
Average value of follow-ons in 2003: $72.28M | ||||||||
| ||||||||
Notes: | ||||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||||||
@ This column reflects the shares outstanding following the offering, when disclosed. | ||||||||
% Market capitalization calculated is based on the offering price; N/A = Not available; CDNX = Canadian Venture Exchange | ||||||||
1. Bioxel completed a public offering of about 13.6M shares at C70 cents per share. The offering includes an overallotment option of 15%. | ||||||||
2. Inspire raised $77.63M with an offering of 5.75M shares, which includes the underwriters' overallotment option for 750,000 shares. | ||||||||
3. The Medicines Co. raised $85.75M in a public offering of 4.9M shares. Underwriters have an overallotment option for 697,280 shares. |
II. FILED AND PENDING | ||||||
Company |
Date Filed |
Shares/ |
Price Range |
Shares Out (M)@ |
Lead, Other |
Value |
| ||||||
INITIAL OFFERINGS | ||||||
Stem Genetics |
7/18/02 |
1.5S |
$7 |
32.3 |
Self-underwritten |
$10.5 |
| ||||||
ViaCell Inc. |
1/30/02 |
N/A |
N/A |
N/A |
UBS Warburg Banc of America Securities U.S. Bancorp Piper Jaffray |
$115 |
|
|
|||||
FOLLOW-ON OFFERINGS | ||||||
Aphton Corp. |
7/8/02 |
5S |
$6.50 |
25.1 |
N/A |
$32.5 |
| ||||||
Ariad |
1/9/02 |
3S |
$5.28 |
35.4 |
N/A |
$15.84 |
| ||||||
Biomira Inc. |
5/2/02 |
N/A |
N/A |
53.4 |
N/A |
C$150 (US$97.84) |
|
||||||
BioPure |
3/6/03 |
10S |
$3.84 |
N/A |
N/A |
$38.4 |
| ||||||
Celgene |
12/21/01 |
N/A |
N/A |
75.6 |
N/A |
$500 |
| ||||||
Cell Genesys |
12/23/02 |
N/A |
N/A |
N/A |
N/A |
$150 |
| ||||||
Cell Pathways |
2/7/01 |
N/A |
N/A |
N/A |
N/A |
$25 |
| ||||||
Centrex Inc. |
2/24/03 |
N/A |
N/A |
N/A |
HD Brous & Co. |
$20 |
| ||||||
Cepheid |
12/21/01 |
N/A |
N/A |
26.56 |
N/A |
$35 |
| ||||||
Cerus Corp. |
8/13/01 |
N/A |
N/A |
15.7 |
N/A |
$300 |
| ||||||
CollaGenex |
10/26/01 |
0.965S |
$8.01 |
N/A |
Kingsbridge Capital |
$7.7 |
|
||||||
Cubist |
3/7/03 |
N/A |
N/A |
N/A |
N/A |
$75 |
| ||||||
Cytogen |
10/26/01 |
10S |
$2.50 |
79.8 |
N/A |
$25 |
| ||||||
Dendreon Corp. (DNDN)16 |
1/22/03 |
N/A |
N/A |
N/A |
N/A |
$75 |
| ||||||
EntreMed Inc. |
5/10/02 |
N/A |
N/A |
N/A |
N/A |
$50 |
| ||||||
Exelixis Inc. |
7/30/01 |
N/A |
N/A |
49.2 |
N/A |
$150 |
| ||||||
Genaera Corp. |
11/21/01 |
N/A |
N/A |
38.9 |
N/A |
$50 |
| ||||||
Genaissance Pharmaceuticals Inc. (GNSC)20 |
10/18/01 |
N/A |
N/A |
22.8 |
N/A |
$35 |
| ||||||
GenVec Inc. |
12/19/02 |
N/A |
N/A |
N/A |
N/A |
$25 |
| ||||||
Geron Corp. |
1/30/02 |
N/A |
N/A |
N/A |
N/A |
$150 |
| ||||||
Hemispherx |
1/15/03 |
5S |
$2.16 |
37.6 |
N/A |
$10.8 |
| ||||||
Hollis-Eden |
2/26/02 |
3S |
$8.71 |
N/A |
N/A |
$26.13 |
| ||||||
InSite Vision Inc. (AMEX:ISV)25 |
2/2/01 |
N/A |
N/A |
N/A |
Ladenburg Thalmann (placement agent) |
$40 |
|
||||||
Lexicon Genetics |
11/27/02 |
12S |
$3.98 |
N/A |
N/A |
$47.76 |
| ||||||
Martek Biosciences |
2/4/03 |
N/A |
N/A |
N/A |
N/A |
$100 |
| ||||||
Neurogen Corp. (NRGN)28 |
8/16/02 |
N/A |
N/A |
N/A |
N/A |
$75 |
| ||||||
Northwest |
6/4/02 |
11S |
$3.77 |
17 |
C.E. Unterberg, |
$41.5 |
| ||||||
Pharmos Corp. |
2/4/02 |
N/A |
N/A |
56.6 |
N/A |
$25 |
| ||||||
SciClone |
11/6/01 |
N/A |
N/A |
N/A |
N/A |
$20 |
| ||||||
StemCells |
3/8/02 |
15S |
$2.52 |
25.8 |
N/A |
$37.8 |
| ||||||
Targeted |
12/13/01 |
8.84S |
$2.57 |
N/A |
N/A |
$22.72 |
| ||||||
Triangle |
9/25/02 |
N/A |
N/A |
N/A |
N/A |
$80 |
| ||||||
Tularik Inc. |
8/14/01 |
N/A |
N/A |
49.2 |
N/A |
$250 |
| ||||||
VaxGen Inc. |
11/7/02 |
N/A |
N/A |
N/A |
N/A |
$150 |
| ||||||
III. WITHDRAWN AND POSTPONED | ||||||
Company |
Date Filed/Date |
Shares/Units |
Price |
Shares |
Lead, Other |
Value (M) |
| ||||||
INITIAL PUBLIC OFFERINGS | ||||||
MitoKor Inc. |
3/8/02 3/25/03 |
N/A |
N/A |
N/A |
RBC Capital Markets Lazard Freres Legg |
$60 |
|
|
|||||
| ||||||
Notes: | ||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||||
* Stock symbols for companies seeking to complete IPOs are proposed. | ||||||
@ This column reflects the shares outstanding following the offering, when disclosed. | ||||||
N/A = Not available, applicable or reported. | ||||||
AMEX = American Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange | ||||||
1. Stem Genetics filed for an IPO to raise $10.5M. It intends to go public on the Over-the-Counter Bulletin Board, but did not specify a proposed symbol in its SEC filing. | ||||||
2. ViaCell filed for a $115M IPO. No further details were disclosed. | ||||||
3. Aphton filed a shelf registration statement to sell up to 5M shares at a maximum amount of $6.50 per share. The company privately placed $5M in shares in September 2002 and $1.52M in shares in February 2003. | ||||||
4. Ariad filed a shelf registration statement to sell up to 3M shares. At the Jan. 8, 2002, closing stock price, it would raise $15.84M. | ||||||
5. Biomira filed a $150M shelf prospectus in Canada. | ||||||
6. BioPure registered to sell up to 10M shares of common stock through a shelf registration. Based on the March 6, 2003, closing stock price of $3.84, the offering would raise $38.4M. | ||||||
7. Celgene filed a universal shelf registration statement to offer and sell common stock, debt securities and convertible debt securities, up to a total value of $500M. | ||||||
8. Cell Genesys filed a shelf registration statement allowing it to issue, from time to time, up to $150M of securities. | ||||||
9. Cell Pathways filed a shelf registration statement for the sale of $25M in common stock. The company privately placed $4.4M in shares in September 2002. | ||||||
10. Centrex plans to raised $20M with HD Brous as its managing underwriter. | ||||||
11. Cepheid filed a shelf registration statement to offer and sell up to $35M of its common stock, preferred stock, debt securities and warrants. | ||||||
12. Cerus filed to sell up to $300M of common stock and debt in a shelf offering. | ||||||
13. The value of CollaGenex's proposed offering, $7.7M, is based on the Oct. 26, 2001, closing stock price of $8.01. CollaGenex privately placed 119,335 shares in May 2002, raising $1M. It placed 32,187 shares in June 2002, raising $266,667. | ||||||
14. Cubist filed a shelf registration statement to sell up to $75M in stock. | ||||||
15. Cytogen filed to offer 10M shares at about $2.50 each in a shelf registration statement. It privately placed 3M shares in January 2002, and another 4.17M shares in June 2002. | ||||||
16. Dendreon filed a shelf registration statement with the SEC to sell $75M in stock from time to time. | ||||||
17. EntreMed filed a $50M shelf registration statement, allowing it to offer securities from time to time in the form of common stock, preferred stock or warrants to purchase securities. | ||||||
18. Exelixis filed a shelf registration statement to sell up to $150M in common stock. | ||||||
19. Genaera filed a universal shelf registration statement for the sale of up to $50M in common stock, preferred stock or warrants to purchase common stock or preferred stock. It privately placed $16.5M in shares in April 2002. | ||||||
20. Genaissance filed a shelf registration statement to offer and sell common stock, preferred stock, debt or warrants, up to a value of $35M. | ||||||
21. GenVec filed a $25M shelf registration statement with the SEC. | ||||||
22. Geron filed a prospectus for the sale of up to $150M in debt securities, common or preferred stock and warrants. | ||||||
23. Hemispherx filed to register 5M shares of common stock. The value, $10.8M, is based on the proposed maximum offering price. | ||||||
24. Hollis-Eden filed a shelf registration statement to sell up to 3M shares and warrants from time to time. The value is based on the proposed maximum offering price. | ||||||
25. InSite filed a shelf registration statement in February 2001 to sell $40M in stock. | ||||||
26. Lexicon Genetics filed a shelf registration statement with the SEC to sell up to an aggregate of 12M shares of common stock from time to time. The value, $47.76M, is based on the proposed maximum aggregate offering price per share of $3.98. | ||||||
27. Martek filed a shelf registration statement to raise up to $100M. | ||||||
28. Neurogen filed for a $75M universal shelf registration statement. | ||||||
29. Northwest expects to offer 11M shares as part of a lock-up agreement with the underwriter from the company's December 2001 initial public offering. The value, $41.5M, is based on the June 3, 2002, closing stock price of $3.77. | ||||||
30. Pharmos filed a shelf registration statement to sell up to $25M of common stock, preferred stock, debt securities and/or warrants. | ||||||
31. SciClone filed to sell up to $20M in common and preferred stock, debt securities and warrants from time to time through a shelf offering. SciClone privately placed $10.62M in shares in June 2002. | ||||||
32. StemCells filed with the SEC to sell up to 15M shares to raise a maximum of $37.8M. Further details were not disclosed. | ||||||
33. Targeted Genetics filed a shelf registration statement for the sale of up to about 8.84M shares of common stock. The value is based on the Jan. 22, 2002, closing stock price of $2.57. | ||||||
34. Triangle filed a shelf registration statement with the SEC to sell up to $80M in common and preferred stock. | ||||||
35. Tularik filed to sell up to $250M in common stock and debt securities. It raised $27.2M in October 2002 with an offering of 4M shares. | ||||||
36. VaxGen filed a shelf registration statement for $150M in common stock, preferred stock, debt securities and warrants. Further details were not disclosed. | ||||||
37. MitoKor withdrew its initial public offering due to unfavorable market conditions. |